Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03567135|
Recruitment Status : Recruiting
First Posted : June 25, 2018
Last Update Posted : April 23, 2019
|Condition or disease||Intervention/treatment|
|Glioblastoma||Drug: Apatinib Drug: Temozolomide（TMZ）|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||A Retrospective Clinical Study of Postoperative Concurrent Chemoradiotherapy Combined With Anti-angiogenic Drugs in the Treatment of Glioblastoma.|
|Actual Study Start Date :||October 1, 2017|
|Actual Primary Completion Date :||April 1, 2019|
|Estimated Study Completion Date :||October 1, 2019|
Temozolomide concurrent radiochemotherapy Apatinib
These drugs are planned to inhibit the proliferation and metastasis of tumors.
Other Name: Temozolomide（TMZ）
Temozolomide concurrent radiochemotherapy
Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.
- Progression-Free-Survival(PFS) [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months. ]in this Survival Duration neither Progression nor death occurs in the subjects.
- Assessment of brain edema [ Time Frame: From date of randomization until the date of end of the trial, assessed up to 36 months ]The average score of edema grading in patients before and after treatment was calculated separately.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: From date of randomization until the date of end of the trial, assessed up to 36 months ]To observe any adverse events that occurred during the clinical study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03567135
|Contact: Wenmin Ying, Bacheloremail@example.com|
|Fuzhou General Hospital||Recruiting|
|Fuzhou, Fujian, China, 350025|
|Contact: Wenmin Ying, Bachelor 15080015210 firstname.lastname@example.org|